KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Free Cash Flow: 2019-2024

Historic Free Cash Flow for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$187.0 million.

  • AbCellera Biologics' Free Cash Flow fell 29.80% to -$61.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.1 million, marking a year-over-year increase of 22.42%. This contributed to the annual value of -$187.0 million for FY2024, which is 54.73% down from last year.
  • AbCellera Biologics' Free Cash Flow amounted to -$187.0 million in FY2024, which was down 54.73% from -$120.8 million recorded in FY2023.
  • AbCellera Biologics' Free Cash Flow's 5-year high stood at $206.7 million during FY2022, with a 5-year trough of -$187.0 million in FY2024.
  • For the 3-year period, AbCellera Biologics' Free Cash Flow averaged around -$33.7 million, with its median value being -$120.8 million (2023).
  • Per our database at Business Quant, AbCellera Biologics' Free Cash Flow skyrocketed by 1,329.91% in 2021 and then tumbled by 158.45% in 2023.
  • AbCellera Biologics' Free Cash Flow (Yearly) stood at $13.0 million in 2020, then soared by 1,329.91% to $186.1 million in 2021, then climbed by 11.05% to $206.7 million in 2022, then slumped by 158.45% to -$120.8 million in 2023, then tumbled by 54.73% to -$187.0 million in 2024.